Citations
1 publicationsPublications from researchers using this productDescription
5-(N,N-Hexamethylene)-amiloride is a potent inhibitor of the Na+/H+ exchanger and is toxic to tumor cells [1]. 5-(N,N-Hexamethylene)-amiloride can inhibit DNA synthesis in regenerating liver and induce cell apoptosis, while activating the activity of Jun N-terminal kinase (JNK)[2]. 5-(N,N-Hexamethylene)-amiloride has been widely used to inhibit the growth of Cryptococcus strains and as a starting point for antifungal drug development to develop new analogues with high antifungal activity[3]. 5-(N,N-Hexamethylene)-amiloride has fluorescent properties and can regulate intracellular acidity, which can be used as a self-biomarker of pH changes in cellular studies[4].
In vitro, 5-(N,N-hexamethylene)-amiloride treatment for 48 hours inhibited the replication of mouse hepatitis virus (MHV) and human coronavirus 229E (HCoV-229E) in L929 cells, with EC50 values of 3.91μM and 1.34μM, respectively[5]. Treatment of RPMI-8226 cells with 20μM 5-(N,N-hexamethylene)-amiloride for 48 hours led to cell proliferation inhibition, and caused intracellular acidification[6]. 80µM of 5-(N,N-hexamethylene)-amiloride was applied for 24 hours to induce programmed necrosis in the cultured MCF7 cells through lysosomal and reactive oxygen species (ROS)-dependent mechanisms[7].
In vivo, 5-(N,N-hexamethylene)-amiloride treatment via intraperitoneal injection at a dose of 10mg/kg/day for 14 days suppressed tumor growth in the RPMI-8226 cell xenograft mouse models without affecting body weight[5].
References:
[1] Luo J, Tannock I F. Inhibition of the regulation of intracellular pH: potential of 5-(N, N-hexamethylene) amiloride in tumour-selective therapy[J]. British journal of cancer, 1994, 70(4): 617-624.
[2] Suzuki T, Tsukamoto I. Apoptosis induced by 5-(N, N-hexamethylene)-amiloride in regenerating liver after partial hepatectomy[J]. European journal of pharmacology, 2004, 503(1-3): 1-7.
[3] Vu K, Buckley B J, Bujaroski R S, et al. Antifungal activity of 6-substituted amiloride and hexamethylene amiloride (HMA) analogs[J]. Frontiers in Cellular and Infection Microbiology, 2023, 13: 1101568.
[4] Giansanti V, Santamaria G, Torriglia A, et al. Fluorescence properties of the Na+/H+ exchanger inhibitor HMA (5-(N, N-hexamethylene) amiloride) are modulated by intracellular pH[J]. European Journal of Histochemistry: EJH, 2012, 56(1): e3.
[5] Wilson L, Gage P, Ewart G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication[J]. Virology, 2006, 353(2): 294-306.
[6] Yang N, Dong Z, Xiao W, et al. Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3[J]. Cell Death Discovery, 2024, 10(1): 505.
[7] Rowson-Hodel A R, Berg A L, Wald J H, et al. Hexamethylene amiloride engages a novel reactive oxygen species-and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells[J]. Cancer letters, 2016, 375(1): 62-72.
Protocol
| Cell experiment [1]: | |
Cell lines | MCF-7 cells |
Preparation Method | MCF-7 cells were cultured in high-glucose DMEM medium, supplemented with 10% fetal bovine serum, 100U/ml penicillin and 100μg/ml streptomycin, in a 37°C humidified environment with 5% CO2. MCF-7 cells were seeded at a density of 5×104/ml in 96-well plates. The cells were treated with different concentrations of 5-(N,N-hexamethylene)-amiloride (0, 10, 20, 40, and 80μM). After 24 hours, the cell viability was analyzed. |
Reaction Conditions | 0, 1, 2, 5, 10, and 20μM; 24h |
Applications | 5-(N,N-hexamethylene)-amiloride treatment reduced the cell viability of MCF-7 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Female BALB/c Nude mice |
Preparation Method | Female BALB/c Nude mice, 4-6 weeks old and weighing 20g, were housed in a specific pathogen-free (SPF) animal house at 24±2°C temperature and 55±5% humidity and maintained on a 12h light/12h dark circadian rhythm. Mice received a standard diet and water ad libitum. RPMI-8226 cells (1×107 cells) were injected subcutaneously into the right abdomen of mice. When the tumors were palpable, the mice were randomly divided into two groups: the experimental group received 5-(N,N-hexamethylene)-amiloride (10mg/kg; i.p.) once a day for 14 consecutive days; Mice in the control group were intraperitoneally injected with normal saline. Tumor volume and body weight of mice were analyzed. |
Dosage form | 10mg/kg/day for 14 days; i.p. |
Applications | 5-(N,N-hexamethylene)-amiloride treatment suppressed tumor growth in the RPMI-8226 cell xenograft mouse model without affecting body weight. |
References: | |
Product Documents
Chemical Properties
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
Reviews
Review for 5-(N,N-Hexamethylene)-amiloride
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%
